Rafael (RFL) vs. Its Competitors Head to Head Survey

Rafael (NYSE:RFL) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Rafael to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings for Rafael and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1	0	0	0	1.00
Rafael Competitors	7769	13858	25732	1032	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 23.43%. Given Rafael’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Rafael has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Rafael and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rafael	$870,000.00	-$29.64 million	-1.93
Rafael Competitors	$3.55 billion	$3.17 billion	548.05

Rafael’s rivals have higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Rafael and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rafael	-3,390.73%	-39.52%	-33.73%
Rafael Competitors	-2,372.59%	-220.83%	-15.99%

Insider & Institutional Ownership

11.3% of Rafael shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 32.9% of Rafael shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Rafael has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Rafael’s rivals have a beta of -4.16, indicating that their average stock price is 516% less volatile than the S&P 500.

Summary

Rafael rivals beat Rafael on 10 of the 13 factors compared.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.